P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY. (5th April 2022)

Record Type:: Journal Article
Title:: P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY. (5th April 2022)
Main Title:: P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
Authors:: Rodríguez-Otero, P
San-Miguel, J
Anderson, LD
Lonial, S
Truppel-Hartmann, A
Sanford, J
Rowe, E
Campbell, TB
Munshi, N
Abstract:
Is Part Of:: HemaSphere. Volume 6(2022)Supplement 2
Journal:: HemaSphere
Issue:: Volume 6(2022)Supplement 2
Issue Display:: Volume 6, Issue 2 (2022)
Year:: 2022
Volume:: 6
Issue:: 2
Issue Sort Value:: 2022-0006-0002-0000
Page Start:: 22
Page End:: 23
Publication Date:: 2022-04-05
Subjects:: Hematology -- Periodicals
616.15005
Journal URLs:: https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:: 10.1097/01.HS9.0000829656.69351.86 ↗
Languages:: English
ISSNs:: 2572-9241
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 21663.xml